Urinary incontinence therapy

Abstract

The invention includes a method of treating neurogenic urinary dysfunction that comprises contacting urinary bladder mucosa of a patient afflicted with neurogenic urinary dysfunction with an effective dose of a homovanilloid compound, in particular a compound selected from the group RTX, TYX, 20-homovanillyl-mezerein or 20-homovanillyl-12-deoxyphorbol-13-phenylacetate. The invention includes treatment of urge incontinence due to detrusor hyperreflexia (DH). The invention also includes treatment of sensory hypersensitivity of the bladder resulting from prostate hypertrophy or interstial cystitis, as well as other neurogenic conditions resulting in increased micturition frequency or decreased bladder capacity, with or without frank incontinence.

1 . A kit for intravesicular instillation comprising, a first container containing a unit dose of a therapeutic compound selected from the group resiniferatoxin, tinyatoxin, 20-homovanillyl-mezerein or 20-homovanillyl-12-deoxyphorbol-13-phenylacetate in a solution concentrate or dry powder form and a second container containing a physiologically compatible diluent capable of dissolving and maintaining in solution the therapeutic compound, the volume of said diluent being sufficient for intravesicular instillation of the unit dose and providing a concentration of the therapeutic compound of from 0.05 μM to 2.0 μM upon mixing the diluent with the therapeutic compound, and means for combining the diluent with the stock solution or lyophilized powder under sterile conditions.  
     
     
         2 . The kit of  claim 1  wherein the first container contains a solution of resiniferatoxin dissolved in ethanol at a concentration of from 0.5 μM to 20 μM and the second container contains 100 ml of normal saline.  
     
     
         3 . The kit of  claim 1  wherein the first container contains a lyophilized power comprising from 0.005 μmole to 0.2 μmole resiniferatoxin and the second container contains 100 ml of 10% (v/v) ethanol in normal saline.  
     
     
         4 . The kit of  claim 1  further comprising means for transferring an instillation dose of the therapeutic compound to a patient.